Next Article in Journal
Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities—A Review
Next Article in Special Issue
miR-29a-3p/THBS2 Axis Regulates PAH-Induced Cardiac Fibrosis
Previous Article in Journal
Transcriptomic Analysis of the Differential Nephrotoxicity of Diverse Brominated Flame Retardants in Rat and Human Renal Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 18
10.3390/ijms221810048
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension

by
Anna Krzyżewska
1,*,
Marta Baranowska-Kuczko
1,2,
Krzysztof Mińczuk
1 and
Hanna Kozłowska
1
1
Department of Experimental Physiology and Pathophysiology, Medical University of Białystok, 15-222 Białystok, Poland
2
Department of Clinical Pharmacy, Medical University of Białystok, 15-222 Białystok, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(18), 10048; https://doi.org/10.3390/ijms221810048
Submission received: 8 September 2021 / Revised: 14 September 2021 / Accepted: 15 September 2021 / Published: 17 September 2021
(This article belongs to the Special Issue Advances Research on Pulmonary Hypertension)
Browse Figures
Versions Notes

Abstract

Currently, no treatment can completely cure pulmonary hypertension (PH), which can lead to right ventricular failure and, consequently, death. Therefore, searching for new therapies remains important. Increased resistance in pulmonary circulation is mainly caused by the excessive contraction and proliferation of small pulmonary arteries. Cannabinoids, a group of lipophilic compounds that all interact with cannabinoid receptors, exert a pulmonary vasodilatory effect through several different mechanisms, including mechanisms that depend on vascular endothelium and/or receptor-based mechanisms, and may also have anti-proliferative and anti-inflammatory properties. The vasodilatory effect is important in regulating pulmonary resistance, which can improve patients’ quality of life. Moreover, experimental studies on the effects of cannabidiol (plant-derived, non-psychoactive cannabinoid) in animal PH models have shown that cannabidiol reduces right ventricular systolic pressure and excessive remodelling and decreases pulmonary vascular hypertrophy and pulmonary vascular resistance. Due to the potentially beneficial effects of cannabinoids on pulmonary circulation and PH, in this work, we review whether cannabinoids can be used as an adjunctive therapy for PH. However, clinical trials are still needed to recommend the use of cannabinoids in the treatment of PH.

1. Introduction

Pulmonary hypertension (PH) refers to a group of clinical symptoms caused by increased blood pressure (BP) in the pulmonary circulation. According to the latest classification, PH is diagnosed, when the mean pulmonary artery pressure (mPAP) at rest is over 25 mmHg, confirmed by right-sided heart catheterization. The World Health Organization (WHO) distinguishes five groups of PH: pulmonary arterial hypertension (PAH), PH due to left-sided heart disease, PH due to chronic lung disease, chronic thromboembolic PH, and PH with unexplained and/or multifactorial pathomechanisms [1,2]. PH often leads to heart failure due to the excessive overload of the right ventricle (RV), which can result in the patient’s death [3]. The development of PH is complex, and its pathogenesis can include the dysfunction of vascular endothelial cells with the excessive contraction of the pulmonary arteries, vascular, and RV remodelling (the proliferation of muscle cells and hypertrophy), inflammation, oxidative stress, and thrombosis [4,5,6].
The current treatments for PH include phosphodiesterase type 5 (PDE-5) inhibitors (e.g., sildenafil), soluble guanylate cyclase (sGC) stimulators (riociguat), endothelin receptor antagonists (ERAs) (e.g., bosentan), prostacyclin (PGI2) analogues (e.g., iloprost), and prostacyclin receptor (IP) agonists (selexipag) [7]. Combination therapy has emerged as the contemporary standard of care in the treatment of PH patients who are mostly symptomatic. However, this therapy does not ensure the long-term normalization of pulmonary resistance, which is an unfavorable prognostic factor. Researchers are currently seeking drugs that not only lower pulmonary resistance, but also have anti-proliferative properties [8]. There is currently no therapy that allows patients to fully recover, and PH is still characterized by high mortality [3]. Therefore, new compounds that act on signalling pathways with documented roles in the pathomechanisms of the disease are currently being sought. The first reports on the relaxing effects of cannabinoids on isolated human pulmonary vessels raised the following question: can cannabinoids be used in the treatment of PH? [9]. Hornig [10] hypothesized that cannabinoids could become an element of PH therapy but noted that we still have too little knowledge on this subject and that further experiments are needed. In this review, based on the latest reports, we explored this hypothesis in more detail.
Cannabinoids have been exploited for centuries for recreational and medicinal purposes. When smoked, cannabinoids mainly cause changes in the central nervous system. Moreover, reports suggest that cannabinoids influence the respiratory and circulatory systems. According to the United States Code (USC), marijuana is defined as all parts of the plant Cannabis sativa L. var. indica and contains about 700 compounds, more than 100 of which are cannabinoids, such as the psychoactive delta-9-tetrahydrocannabinol (THC), non-psychoactive cannabidiol (CBD), tetrahydrocannabivarin, and cannabidivarin. It is believed that marijuana has analgesic, anticonvulsant, and anti-asthmatic properties [11]. Research on the effects of plant-derived cannabinoids (phytocannabinoids) and mammalian-organism-produced endocannabinoids (arachidonic-acid derivatives) has recently received widespread interest. It is already known that the endocannabinoid system (ECS) is upregulated in some types of hypertension, including PH [12], and that the ECS components may have anti-proliferative effects [13].
The aim of this review was to determine what vascular mechanisms are involved in cannabinoid-induced pulmonary vasodilation and what effects of cannabinoids have been observed to date during in vivo studies (including experimental PH) to produce a preliminary evaluation of the usefulness of cannabinoids in the assisted treatment of PH. Another objective of this review was to examine the evidence from experimental and human studies showing what endothelium-dependent mechanisms and/or receptors are involved in cannabinoid-mediated responses in the pulmonary vasculature, including cannabinoid receptors types 1 and 2 (CB1-Rs and CB2-Rs), historically called endothelial cannabinoid receptors (eCB-Rs), transient receptor potential vanilloids 1 and 4 (TRPV1 and TRPV4), peroxisome proliferator-activated receptors-γ (PPAR-γ), and prostanoid receptors. This review only briefly describes the effects of cannabinoids on systemic vessels, as these effects have been discussed in detail in reviews by Stanley et al. [14] and Bondarenko [15].

2. Cannabinoids in the Cardiopulmonary System

Cannabinoids are a group of lipophilic compounds that all interact with cannabinoid receptors (CB-Rs). The current classification of cannabinoids is based on their origin: phytocannabinoids isolated, for example, from Cannabis sativa L. var. indica (e.g., THC and CBD); compounds obtained via chemical synthesis (e.g., abnormal cannabidiol (Abn-CBD); WIN 55,212-2); and components of the ECS, such as endocannabinoids (e.g., 2-arachidonoylglycerol (2-AG), N-arachidonoylethanolamine (anandamide; AEA), and virodhamine (VIR)) and endocannabinoid-like molecules (e.g., noladin ether (2-AGE), N-arachidonoyl-L-serine (ARA-S), oleamide (ODA), and L-alpha-lysophosphatidylinositol (LPI)) [16,17]. The presence of all the components of the ECS in the lungs and pulmonary vessels of animals and humans was previously confirmed by various methods (see Table 1).
The ECS components include, for example, the classic G-protein-coupled cannabinoid receptors CB1-R and CB2-R. The presence of CB1-Rs in the brain, liver, reproductive system, skeletal muscles, and cardiovascular system, including pulmonary vessels, has been confirmed [12,21,22,25]. CB2-Rs have been found in the brain, spleen, and mainly immune system cells [12,25,26,27,28]. Cannabinoids also exert their effects through other receptors such as TRPV1, TRPV4, and PPAR-γ, as well as the G-protein-coupled orphan receptors GPR18, GPR55, and eCB-Rs which are O-1918-sensitive and have not yet been cloned [29]. Endocannabinoids are mainly produced "on demand" through the synthesis of membrane phospholipid precursors [25,30]. Enzymes from the group of diacylglycerol lipases (DAGLs)—DAGL-α and DAGL-β—participate in the synthesis of AEA and 2-AG, respectively. 2-AG is degraded in the pulmonary circulation mainly by the enzyme monoacylglycerol lipase (MAGL), and AEA is mainly degraded by fatty acid amide hydrolase (FAAH) into arachidonic acid (AA) (Table 1) [30,31,32].
Cannabinoids directly exert multidirectional effects on the vascular bed, including pulmonary vessels, through interactions with appropriate receptors and indirectly through the metabolites resulting from the degradation of (endo)cannabinoids. The degradation of endocannabinoids primarily produces AA, which is converted into eicosanoids via the cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (cytP450) pathways. The COX pathway that mediates the formation of PGI2, prostaglandins (PG), and thromboxane A2 (TXA2) plays the most important role in vascular responses [33]. Moreover, Sadowska et al. [19] recently demonstrated the presence of 13 endocannabinoids and endocannabinoid-related lipids in the lungs of control and monoctrotaline (MCT)-induced PH rats. These 13 endocannabinoids were AEA, 2-AG, palmitoyl ethanolamide (PEA), oleoyl ethanolamide (OEA), stearoyl ethanolamide (SEA), inolenoyl ethanolamide (LEA), palmitoleoyl ethanolamide (POEA), N-arachidonoylglycine (NAGly), docosahexaenoyl ethanolamide (DHEA), docosatetraenoyl ethanolamide (DEA), homo-γ-linolenyl ethanolamide (HEA), linoleoylglycerol (2-LG), and eicosapentaenoyl ethanolamide (EPEA), among which OEA, SEA, HEA, DEA, 2-LG, DHEA, POEA, and EPEA were examined for the first time. To date, however, little research has explored the role of the above-mentioned endocannabinoids in the physiology and pathophysiology of the pulmonary circulation.

3. Effects of Cannabinoids on Systemic Vessels

The ECS is unlikely to be the main element regulating the cardiovascular parameters in physiological conditions, although it plays an important role in pathological states [29,34]. The effects of cannabinoids on blood vessels have been studied since the 1990s, and new research continues to emerge. Cannabinoids in systemic circulation cause the relaxation of the blood vessels, which was extensively described by Stanley et al., in 2014. In this review, we focus on papers published after Stanley et al. (Table 2) [14]. The relaxation induced by various cannabinoids might be dependent on the endothelium [22,35,36,37,38,39,40,41,42] and/or receptors (e.g., CB1-Rs) [22,35,37,38,40,41,42,43] (Table 2). The potency of individual compounds depends on the vascular bed and species. As shown in Table 2, according to the negative logarithm of the concentration causing a half-maximum effect (pEC50) value, methanandamide (MethAEA) [42] dilated rat mesenteric arteries (rMAs) most strongly, while the weakest effects were observed for Abn-CBD in rat retinal capillaries [44] and arachidonyl cyclopropylamide (APCA) in rat aortas [43].

4. The Systemic Versus Pulmonary Circulation

As mentioned above, the ECS is located in the pulmonary circulation (for reviews, see Kicman and Toczek [29] and Karpińska et al. [48]) (Table 1), and its endocannabinoid components can cause the relaxation of systemic vessels, resulting in a decrease in BP [12]. Therefore, the question emerges as to whether these components could also have hypotensive effects in the pulmonary circulation. Moreover, cannabinoids can be administered by inhalation. From a pharmacological point of view, this method of delivery could accelerate the effects of their action in the pulmonary circulation. In considering this question, attention should be paid to the similarities and differences between systemic vessels and pulmonary vessels, as such factors can affect the mechanisms of action of cannabinoids. An extremely important element in the structure of pulmonary vessels is the endothelium, which, despite being a mechanical barrier also participates in maintaining proper vascular tone through the synthesis of vasoactive compounds [49]. In PH, there is a notable change in the endothelial synthesis of compounds regulating vascular tone, with a predominance of vasoconstrictors (TXA2, angiotensin II (ANG II), 5-hydroxytryptamine (5-HT), and endothelin 1 (ET-1)) compared to vasodilators (nitric oxide (NO) and PGI2) [4]. Under normal conditions, the pulmonary circulation is a low-pressure, low-resistance, and high-volume system. One of the most important features distinguishing the systemic circulation from pulmonary circulation is the presence of a mechanism that dilates blood vessels in response to hypoxia. Systemic arteries relax with decreased oxygen concentration, while pulmonary vessels constrict in response to hypoxia and increased blood oxygenation, transporting blood to more heavily oxygenated areas. Hypoxia induces hypoxic pulmonary vasoconstriction (HPV) and a hypoxic ventilatory response [50]. If hypoxia is prolonged, as can be the case in various chronic lung diseases, the spasm is accompanied by a remodelling of the vascular system leading to an increase in pulmonary vascular resistance (PVR) and the development of PH. In addition to hypoxia, the susceptibility to develop PH can also be increased by other genetic and environmental factors, even in the absence of a hypoxic stimulus [51].

5. Cannabinoids Affect Pulmonary Circulation

Similarly, as in the systemic circulation, cannabinoids are also shown to have a vasodilating effect in isolated pulmonary vessels (Table 3) [9,21,22,23,24,52,53,54]. Cannabinoids show a concentration-dependent vasodilating effect in human pulmonary arteries (hPAs). As shown in Table 3, according to the pEC50 value in hPAs, LPI [23] has the strongest vasodilatory effect (6.4), while 2-AG [21], AEA (in the presence of AM251) [9], and VIR [53] have similar levels of potency (approximately 5) and Abn-CBD [9] is the least potent. Similar results were obtained in animal pulmonary vessels (see Table 3).
At the outset, it is worth noting that the most frequently used pulmonary vasoconstrictors (i.e., U46619 (an analogue of TXA2) and 5-HT (Table 3)) reflect the vasoconstrictors involved in PH’s pathophysiology (see Section 4). LPI shows the strongest vasodilatory effect, but this effect could be due to the use of phenylephrine for vasoconstriction [23]. Additionally, CBD and LPI cause a time-dependent relaxation of human pulmonary vessels. Single concentrations of CBD [22] and LPI [23] produce an initial relaxation of the vessels of about 20% after 15 min, increasing to about 70% after 120 min.
In addition to the best-known endocannabinoids, in this paper, we show for the first time that the three endocannabinoid-like molecules, i.e., 2-AGE, ARA-S, and ODA, can cause a slowly developing relaxation of the endothelium-intact human pulmonary arteries (hPAs), with the following rank-order of potencies (according to their pEC50 values): AEA (4.8) > 2-AGE (4.6) > ARA-S (4.1) > ODA (<4) (see Figure 1). To date, the vasodilatory effects of ODA [55] and ARA-S [56] have been investigated in rMAs and aortas only. Moreover, 2-AGE was previously shown to relax rabbit pulmonary arteries [52]. 2-AGE may be an interesting focus for future studies on pulmonary arteries since oppositely to unstable 2-AG, 2-AGE does not convert to metabolites with vasoconstrictor activity in rabbit pulmonary circulation [18].
Cannabinoids cause multidirectional pulmonary vasodilatory effects mediated by the vascular endothelium and/or the COX-dependent pathway, potassium channels (i.e., calcium-activated potassium channels (KCa) with small (KCa2.3), intermediate (KCa3.1), and large (KCa1.1) conductance), cannabinoid receptors, and others (see Table 3).

6. Endothelium-Dependent Mechanisms of Pulmonary Vasorelaxation

In all the studies performed on isolated hPAs and animal pulmonary arteries (Table 3), the removal of the endothelium impairs vascular relaxation. This suggests the contribution of endothelium-dependent mechanisms. The removal of the vascular endothelium reduces the relaxation induced by the highest concentrations of AEA [24] and VIR [53] in hPAs by approximately 65%. The endothelium was also observed to be involved in CBD- [22], 2-AG- [21], LPI- [23], and Abn-CBD-induced relaxation [9] in hPAs. Similarly, in animal studies, the removal of the endothelium attenuates the relaxation induced by 2-AGE in rabbit pulmonary arteries [52] and by AEA or Abn-CBD in rat pulmonary arteries (rPAs) (see Table 3) [54]. In systemic vessels, endothelium denudation modifies the relaxation effect in 70% of the studies published after Stanley et al. (see Table 2) [14]. In summary, regardless of the species and vasoconstricting factors, the vascular endothelium probably plays an important role in pulmonary vasorelaxation. The mechanisms that could account for the endothelium-dependent vasodilating effects are described below (i.e., the arachidonic-acid-derived pathway, KCa channels, and the involvement of NO (see Table 3)).

6.1. Arachidonic-Acid-Derived Pathway

Several lines of evidence have shown that the endothelium-dependent component of cannabinoid-evoked vasorelaxation may be mediated by arachidonic-acid-derived products that occur as a result of further transformation in the COX-1/COX-2-dependent pathway [57]. The administration of URB597, an FAAH inhibitor, and indomethacin, a non-selective COX-1/COX-2 inhibitor, decreases the relaxation induced by AEA [24] and VIR [53] in hPAs. Indomethacin and nimesulide (a selective COX-2 inhibitor) inhibite the CBD-mediated relaxation of hPAs [22], suggesting the involvement of arachidonic-acid-derived metabolites in relaxation (see Table 3). Similar effects are observed in rPAs, where URB597 and indomethacin were also found to inhibit AEA-induced relaxation [54]. Some of the most important endocannabinoid-related products of the COX-1/2-dependent pathway are PGI2 and prostaglandins (mainly PGE2) [58]. PGE2 exerts dichotomous vascular activities and may cause vasorelaxation via the prostaglandin receptor EP2 or EP4 [22,59] and vasoconstriction via the receptor EP1 or EP3 [18]. Notably, as a result of the weakened endothelial functions in PH, the concentration of PGI2 decreases. By binding with its membrane receptor, PGI2 stimulates adenylate cyclase, which produces cyclic adenosine monophosphate (cAMP), which not only induces relaxation, but also exhibits anti-proliferative properties [60]. The involvement of IP receptors in the AEA-induced relaxation of hPAs [24] and rPAs [54] was also confirmed (Table 3). In addition to the above, it was proposed that CBD-dependent pulmonary vasodilation is mediated by the stimulation of the IP and EP4 receptors, as antagonists of these receptors were observed to reduce the relaxation effect (see Table 3) [22].
Notably, in an isolated mouse perfused lung model, AEA induces the contraction of the pulmonary vessels through the products of FAAH-induced AEA degradation [20]. The authors showed that AEA does not modulate vascular tone in large isolated pulmonary arteries (preconstricted with phenylephrine). In addition, hypoxia can also increase the levels of an important precursor of vasoconstrictive eicosanoids and AA in pulmonary artery smooth muscle cells (PASMCs). Moreover, the hypoxia-induced elevation of AEA and AA is restricted to PASMCs and does not occur in pulmonary endothelial cells [20]. An increase in PAP under the influence of AEA was shown in an isolated perfused rabbit lung model; the authors suggested that this increase may be related to AEA’s degradation into vasoconstricting metabolites [18], as COX-1/2-dependent-pathway metabolites might also possess vasoconstriction potency. However, more research is necessary to conclusively determine why AEA presents completely different effects between isolated vessels and the perfused lung model.

6.2. Vasorelaxation’s Dependence on Calcium-Dependent Potassium Channels

KCa are important in regulating pulmonary vascular tone, and impaired KCa function can lead to PH [61]. The ability of high KCl concentrations to abolish or reduce the vasorelaxation induced by cannabinoids, including AEA [24,54], VIR [53], CBD [22], and Abn-CBD [9,54], suggests the direct or indirect involvement of potassium channels (including KCa). Charybdotoxin and apamin, which are KCa1.1 and KCa3.1 or KCa2.3 inhibitors, respectively, reduce the vasorelaxant effects of Abn-CBD [9] and VIR in hPAs [53] (Table 3). This reduction may be related to the involvement of endothelium-dependent hyperpolarization (EDH) [62], which is sensitive to the combined administration of apamin and charybdotoxin in the pulmonary vasorelaxation mechanism. Iberiotoxin, which is an inhibitor of KCa1.1 channels, reduces AEA-induced vasorelaxation in the human pulmonary vascular bed [24]. Similarly, iberiotoxin and TRAM-34, which are inhibitors of KCa1.1 and KCa3.1, respectively, significantly reduce the CBD-induced relaxation of hPA (see Table 3) [22].
In addition to the above-mentioned KCa, the expression of the two-pore-domain potassium (K2P) channel was confirmed in rat and human PASMCs [63]. AEA attenuates hypoxia-induced vasoconstriction (which is one of the pathogenetic factors in PH) via the inhibition of the K2P channel in murine intra-acinar and pre-acinar arteries and does not change the vascular calibre under normoxia [63].

6.3. Regulation of Pulmonary Vascular Tension by NO

The incubation of isolated human pulmonary vessels with N G-nitro-l-arginine methyl ester (L-NAME), an endothelial nitric oxide synthase (eNOS) inhibitor, reduces the relaxation induced by AEA [24] and, to a lesser extent, that induced by VIR [53]. A similar effect was observed for AEA in the rPA [54] (see Table 3). Notably, the NO-dependent component of AEA-evoked relaxation may be the result of direct or indirect interactions with PPAR-γ, which stimulates NO production and potentiates NO’s bioavailability [64]. In contrast to the above, it was previously shown that NO does not participate in the vasorelaxation induced by exogenous cannabinoids, especially that induced by stable analogues such as Abn-CBD [9]. Similarly, CBD-induced hPA relaxation is also NO-independent [22]. In systemic vessels, NO appears to be involved in the AEA- [38] and CBD-induced [37] relaxation of human mesenteric arteries (hMAs) (Table 2). Similarly, NAGly- [39], CBD- [46], JHW-133-, and APCA-induced [41] relaxation in rMAs was shown to be attenuated by L-NAME administration. In hMAs, L-NAME was shown to attenuate the vasodilatory effects mediated by CBD, and CBD was found to increase eNOS phosphorylation in human endothelial cells [37]. No evidence indicated the involvement of NO in Abn-CBD-mediated relaxation in rat retinal capillaries (see Table 2). These discrepancies in the mechanism of action may be due to differences between the species and structures/properties in different cannabinoid groups (endocannabinoids, phytocannabinoids, and synthetic cannabinoids such as Abn-CBD).

7. Receptor-Mediated Vasodilatation

It was previously suggested that the mechanisms inducing the relaxation of pulmonary vessels under the influence of cannabinoids include CB1-Rs/CB2-Rs [21], other CB receptors such as eCB-Rs [9,37,52,53,54], the cannabinoid-receptor-related orphan G-protein-coupled receptors GPR55 and GPR18 [23], and the non-cannabinoid receptors PPAR-γ [22,23], TRPV1, and TRPV4 [22]. This argument is reinforced by the fact that the presence of these receptors in the endothelium and/or smooth muscle cells was confirmed (Table 1).

7.1. Mechanism Dependent on CB1-Rs and CB2-Rs

The administration of the CB1-R antagonist AM251 and/or rimonabant attenuates 2-AG-mediated relaxation in hPAs [21], 2-AGE, and Abn-CBD-mediated relaxation in rabbit pulmonary arteries [52], suggesting the involvement of these receptors in vasodilation (see Table 3). CB1-R antagonists do not affect the AEA-induced relaxation of hPAs [24] or the AEA- [54], CBD- [22], and Abn-CBD-induced [54] relaxation of rPAs. Moreover, the administration of rimonabant at a concentration of 100 nM does not reduce VIR-induced relaxation, which excludes the participation of CB1-Rs. However, this effect was observed at a concentration of 5 μM; however, a higher concentration of rimonabant antagonizes eCB-Rs (see Table 3) [53]. Additionally, WIN 55,212-2, a synthetic agonist of CB1-Rs and CB2-Rs, does not induce the relaxation of pulmonary vessels [53].
There are indications of a previously unknown CB1-R-dependent endocannabinoid-mediated potential protective mechanism against excessive vasoconstriction (mainly mediated by 2-AG). AM251 attenuates 2-AG-induced vasorelaxation, indicating the involvement of CB1-Rs in the relaxation mechanism (see Table 3) [21]. It was suggested that vasoconstrictors such as TXA2 and ANG II stimulate the Gq/11 protein, stimulating the release of 2-AG from the vascular endothelium. By acting on CB1-Rs, 2-AG produces vasodilation in hPAs [21,48], which may play a protective role against excessive increases in pressure in the pulmonary circulation through a so-called negative-feedback mechanism. The administration of JZL184, a MAGL inhibitor, enhances the relaxant effects of 2-AG in hPAs, suggesting that the vasorelaxant effect is caused by undegraded 2-AG, not the metabolites of 2-AG. Moreover, this experiment further confirmed that 2-AG, not AEA, is responsible for this effect, because, as described above, AEA does not act through CB1-Rs (see Table 3). In addition, contractions induced by U46619 in hPAs with preserved endothelium are enhanced by the presence of the DAGL inhibitor RHC80267 (responsible for the formation of 2-AG). This effect was not observed in pulmonary arteries with the endothelium removed. Experiments with RHC80267 suggested that the rapid, contractile-stimulated synthesis of 2-AG and its release from endothelial cells plays a protective role [21].
Conversely, in systemic vessels, CB1-Rs are involved in AEA- [38], CBD- [22,37], Meth-AEA- [42,47], and ACPA-induced relaxation [41] in human and animal mesenteric arteries (see Table 2). In systemic circulation, however, it has not yet been confirmed that the mechanism underlying the 2-AG-induced relaxation of hMAs depends on CB1-Rs. Moreover, it was suggested that this effect is exerted by metabolites resulting from the degradation of 2-AG in the COX-1-dependent pathway [14].
Notably, to date, no studies have confirmed the role of CB2-Rs in the cannabinoid-induced relaxation of isolated pulmonary vessels (Table 3) [22,24,53,54]. However, Zoratti et al. [65] demonstrated the presence of CB2-Rs in a calf pulmonary artery endothelial (CPAE) cell line; these CB2-Rs were found to be 86% homologous to the corresponding regions of the human CB2-R sequences. The functional analysis also showed that AEA initiates Ca2+ signalling in CPAE cells through the CB2-R activation. Although it is generally accepted that CB2-Rs are not directly involved in vascular relaxation [37], it was previously reported that the administration of the CB2-R inhibitor AM630 reduces the CBD-induced vasorelaxant effect in rat femoral arteries [45]. However, because CBD does not direclty activate CB2-Rs, the specific mechanism of action is unknown; it was suggested that CBD changes the function of this receptor.

7.2. Other G-Protein-Dependent Receptors

Previously, a cannabinoid endothelial receptor sensitive to O-1918 was considered to be a site of action for vasorelaxation. However, since this putative receptor has not yet been cloned, it remains uncertain whether it can truly be classified as a receptor. It was observed that the administration of the eCB-R antagonist O-1918 [9,53,54] reduces the AEA- [24] and VIR-induced [53], but not CBD-induced, relaxation of hPAs (see Table 3) [22]. Interestingly, three independent studies exploring the effects of Abn-CBD on the pulmonary vessels of humans [9], rabbits [52], and rats [54] suggested that this relaxation effect may depend on the presumed eCB-R, because the administration of O-1918 impairs relaxation. The administration of the pertussis toxin (PTX) (400 ng/mL, for 2 h) partially inhibits the Abn-CBD-induced vasodilation of endothelium-intact human arteries, which confirmed the involvement of a Gi/Go-coupled eCB-Rs [9]. These differences in the vascular mechanisms of action of CBD and Abn-CBD, coupled with the fact that CBD is a partial agonist/antagonist of GPR18 while Abn-CBD is an agonist of GPR18, suggest that the unclassified eCB-R is probably GPR18 [15,29]. However, the putative eCB receptor antagonist may act independently of the G-protein-coupled receptors (GPCRs). Additionally, this receptor influences the functional properties of many ion channels and transporters located in the vascular system [15,66]. Reports that O-1918, after endothelial removal, also attenuates the vasodilatory effect suggest that O-1918’s site of action may be in the vascular smooth muscle [67]. Additionally, it was shown that O-1918 is an inhibitor of the Na+/Ca2+ exchanger [68] and inhibits the activity of KCa1.1 channels [69], which may contribute to the regulation of vascular tone. However, this issue has not yet been unequivocally resolved in the literature [15,29,66,70].
Another receptor with confirmed expression in hPAs is GPR55, which exhibits vasorelaxant properties in the above-mentioned arteries (Table 1). LPI, an endogenous non-cannabinoid agonist of the GPR55 receptors, depending on concentration and time, causes the relaxation of isolated hPAs. The participation of GPR55 receptors in functional studies was confirmed by the use of their antagonist CID16020046, which significantly reduces the relaxation responses of hPAs stimulated with LPI [23].

7.3. Other G-Protein-Independent Receptors

In the pulmonary vessels, according to the current literature, only CBD causes relaxation dependent on TRPV1 receptors (see Table 3) [22]. Importantly, the presence of the TRPV1 receptors in human pulmonary vessels was confirmed (see Table 1) [22]. Capsazepine, an antagonist of TRPV1 receptors, was not observed to reduce the rPA [54] and hPA [24,53] relaxation induced by endocannabinoids such as AEA and VIR (Table 3).
The role of TRPV1 receptors in PH is unclear. Zhang et al. [71] suggested that, on the one hand, TRPV1 induces an increase in intracellular calcium ([Ca2+]i) in PASMCs and can cause vascular contractions, as well as promoting smooth muscle cell proliferation, which can lead to PH. On the other hand, the activation of TRPV1 in sensory nerves can release neuropeptides, including the calcitonin-gene-related peptide (CGRP) [71]. CGRP causes the relaxation of blood vessels and inhibits their proliferation, which may be beneficial in PH [71]. Moreover, pre-treatment with capsaicin, a specific activator of TRPV1, was found to reverse PH by alleviating inflammation [72]. Thus, the potential role of TRPV1 in PH should be further investigated.
The presence of TRPV4 receptors and their involvement in vascular relaxation mechanisms was confirmed by Addison et al. [73]. The pharmacological activation of TRPV4 receptors with the selective agonist GSK1016790A results in the relaxation of endothelium-intact rPAs preconstricted with phenylephrine [73]. In addition, the TRPV4-receptor antagonist HC067047 reduces the vasodilatory response to GSK1016790A [73,74]. Despite the above, it has not been confirmed that TRPV4 receptors participate in CBD-induced relaxation since the administration of RN1734, which antagonizes the TRPV4 receptors, does not affect relaxation [22]. Conversely, Ho et al. [36] confirmed that these receptors participate in the rMA relaxation induced by 2-AG through two antagonists, HC067047 and RN1734 (see Table 2). Moreover, TRPV4 receptors are involved in the proliferation and migration of PASMCs and may serve as a crucial target in the treatment of PH [75].
Recently, research has suggested the potential benefits of stimulating PPAR-γ receptors to alleviate PH. The PPAR-γ antagonist GW9662 reduces the time-dependent relaxation of hPAs induced by CBD (10 μM) (see Table 3) [22]. Previous studies on the potential beneficial effects of PPAR-γ receptor agonists demonstrated the PPAR-γ-receptor-mediated relaxation of human pulmonary vessels preconstricted with U46619 [76]. In addition to the above, PPAR-γ agonists exert beneficial effects on pulmonary vascular remodelling and lung morphology. Indirect evidence for the utility of PPAR-γ agonists in the treatment of PH lies in the fact that the deletion of this receptor in mouse smooth muscle [77] and endothelial cells caused the hypertrophy of the small distal pulmonary arteries and, consequently, induced PH [78]. PPAR-γ ligands interfere with the production of matrix metalloproteinases that can be activated by elastase, which was shown to prevent and reverse PH in rats. In addition to the above, PPAR-γ has anti-inflammatory properties, which include the suppression of factors related to PH, such as interleukin-6 (IL-6) and monocyte chemoattractant protein (MCP-1). PPAR-γ also protects endothelial cells against apoptosis [79]. PPAR-γ expression was found to be reduced in patients with primary and secondary PH [80], and hypoxia was found to reduce PPAR-γ expression in human pulmonary vessels [81,82]. CBD is a functional PPAR-γ agonist and was observed to cause the time-dependent relaxation of rat aortas. This effect is inhibited by the PPAR-γ antagonist GW9662, which confirms the effect of PPAR-γ on aortic relaxation [83].

8. Cannabinoids in PH—In Vivo and In Vitro Studies

Although the effects of cannabinoids on isolated vessels have been fairly well researched, there are still very few in vivo studies. In this review, the terms “PAH” and “PH” are reserved for human and experimental conditions, respectively [84,85]. An interesting look at the use of cannabinoids in PH therapy was presented in the latest study on CBD administration in an animal model of PH [19]. This PH model is induced in 6-to-8-week-old rats via the subcutaneous administration of 60 mg/kg MCT. The use of MCT to create an experimental model allows for the relatively simple mapping of PH in the human population by selectively damaging pulmonary vessels without adversely affecting systemic blood vessels [84]. The chronic administration of CBD as a prophylactic (see Table 4) improves blood oxygen saturation and lowers right ventricular systolic pressure (RVSP) without impacting systemic BP. CBD also reduces pulmonary arterial hypertrophy by about 30%, without any effects on RV hypertrophy [19], and normalized the plasma concentrations of plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA). This effect is beneficial, because the levels of PAI-1 and t-PA are increased in PH. The above changes may partly correlate with increases in endogenous cannabinoid concentrations and AEA and NAGly in CBD-treated animals [19] (Table 4), because both endocannabinoids can relax the pulmonary [9,24,54] and systemic vessels [38,39,59] (see Table 2 and Table 3). Importantly, the chronic administration of the same dose of CBD does not change the BP or heart rate (HR) in spontaneously hypertensive rats (SHRs), rats with secondary hypertension induced by deoxycorticosterone acetate salt (DOCA salt), or their controls with normal pressure [86].
Lu et al. [87] also suggested the potential benefits of using CBD (in preventive and therapeutic models; see Table 4) in PH treatment and showed that CBD, in a preventive model, is more effective in decreasing PH phenotypes in PH mice. Mice (in a sugen-hypoxia-induced PH model) and rats (in an MCT-induced PH model) treated with CBD present lower RVSP and reduce RV and pulmonary-artery hyperproliferation. CBD also reduces the mRNA levels of inflammatory mediators such as IL-6 and tumour necrosis factor-α (TNF-α) in mouse lung tissue (see Table 4) [87]. Moreover, CBD (10 μM) was shown to inhibit the hyperproliferation of mouse PASMCs without any harmful effects on normal PASMCs. CBD was also found to recover dysfunctional mitochondria under conditions of hypoxia and relieve oxidative stress in human and mouse PASMC cell cultures. The effectiveness of CBD was also compared to that of drugs commonly used for PH, and the results suggest that CBD is as effective as bosentan or beraprost [87].
Other studies have shown an increase in PAP after the administration of AEA and 2-AG in isolated, ventilated, and buffer-perfused rabbit lungs. 2-AG showed more pronounced effects at lower concentrations. Anandamide presents a similar relationship, and an increase in PAP was observed, depending on the dose of AEA (Table 4). The authors suggested that the products from the breakdown of endocannabinoids are further metabolized to PGE2 and TXA2 (via COX-2), with vasoconstriction properties, in pulmonary arteries [18]. A similar theory was presented by Wenzel et al. [20]. According to the authors, AEA is a mediator of HPV via FAAH-dependent metabolites and is involved in the generation of PH, as discussed above.
RV failure is undoubtedly one of the worst consequences of PH. Duerr et al. [88] suggested that the ECS may play an important role in PH related to the endocannabinoid–CB2-R axis. In a mouse PH model induced by left pulmonary artery occlusion, researchers found that CB2-R-deficient (Cnr2−/−) mice had stronger cardiomyocytic hypertrophy and an increased Fulton’s index. The above-described effects of cannabinoids on pulmonary vascular tone and new reports on the potential beneficial effect of CBD on the animal model of PH may provide a foundation for further research. Among cannabinoids, it may be useful to explore new therapeutics for PH, especially when it is possible to create synthetic cannabinoids with selective and more concentrated actions.

9. Conclusions

(Endo)cannabinoids play a role in regulating pulmonary vascular tone through endothelium-dependent and/or receptor-based mechanisms (Figure 2), which may contribute to decreasing pulmonary resistance. Moreover, the endocannabinoid negative-feedback mechanism in pulmonary arteries was found to be responsible for attenuating agonist-induced vasoconstriction, which may also play an important role in the treatment of PH. CBD, which was approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of drug-resistant seizures and spasticity in adult patients with multiple sclerosis, also exerts a protective effect on the vascular endothelium, decreases RVSP and/or heart remodelling and increases saturation in experimental PH, in addition to its vasorelaxant effects on pulmonary arteries. Therefore, (endo)cannabinoids represent a potential new treatment strategy as an add-on therapy for PH. Nevertheless, it should be emphasized that no clinical trials with cannabinoids in PH have yet been conducted; thus, their therapeutic potential has not been yet translated into clinical practice. In addition, single experimental studies showed that AEA and 2-AG can contract vessels and/or increase PAP. Further research, both experimental and clinical, is needed to explain these inaccuracies.

Author Contributions

Conceptualization, A.K., M.B.-K. and H.K.; writing—the original draft preparation, A.K.; writing—review and editing, A.K., M.B.-K., K.M. and H.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Medical University of Białystok (Poland) (grant number: SUB/1/DN/21/001/2213).

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

2-AGEnoladin ether
Abn-CBDabnormal-cannabidiol
APCAarachidonylcyclopropylamide
ARA-Sarachidonoyl-L-serine
CB1,2-Rcannabinoid receptor types 1 and 2
CBDcannabidiol
CBRscannabinoid receptors
DAGL-α,βdiacylglycerol lipases α,β
DHEAdocosahexaenoyl ethanolamid
DEAdocosatetraenoyl ethanolamide
ECSendocannabinoid system
EDHendothelium-dependent hyperpolarization
EPEAeicosapentaenoyl ethanolamide
ERAsendothelin receptor antagonists
HEAhomo-γ-linolenyl ethanolamide
hPAshuman pulmonary arteries
LEAinolenoyl ethanolamide
2-LGlinoleoylglycerol
LPI Lalpha-Lysophosphatidylinositol
MCTmonocrotaline
MethAEAmethanandamide
NAGly Narachidonoyl glycine
ODAoleamide
OEAoleoyl ethanolamide
PAHpulmonary arterial hypertension
POEApalmitoleoyl ethanolamide
PAPpulmonary arterial pressure
PASMCspulmonary artery smooth muscle cells
PEAethanolamide
PHpulmonary hypertension
PPAR-γperoxisome proliferator-activated receptor-γ
PVRpulmonary vascular resistance
rPArat pulmonary artery
RVSPright ventricular systolic pressure
SEAstearoyl ethanolamide
U46619analogue of thromboxane A2
VIRvirodhamine

References

  1. Mandras, S.A.; Mehta, H.S.; Vaidya, A. Pulmonary Hypertension: A Brief Guide for Clinicians. Mayo Clin. Proc. 2020, 95, 1978–1988. [Google Scholar] [CrossRef] [Scilit]
  2. Oliveira, A.C.; Richards, E.M.; Raizada, M.K. Pulmonary hypertension: Pathophysiology beyond the lung. Pharmacol. Res. 2020, 151, 104518. [Google Scholar] [CrossRef] [Scilit]
  3. Dodson, M.W.; Brown, L.M.; Elliott, C.G. Pulmonary Arterial Hypertension. Heart Fail. Clin. 2018, 14, 255–269. [Google Scholar] [CrossRef] [Scilit]
  4. Lan, N.S.H.; Massam, B.D.; Kulkarni, S.S.; Lang, C.C. Pulmonary Arterial Hypertension: Pathophysiology and Treatment. Diseases 2018, 6, 38. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Humbert, M.; Guignabert, C.; Bonnet, S.; Dorfmüller, P.; Klinger, J.R.; Nicolls, M.R.; Olschewski, A.J.; Pullamsetti, S.S.; Schermuly, R.T.; Stenmark, K.R.; et al. Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives. Eur. Respir. J. 2019, 53, 1801887. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Huertas, A.; Tu, L.; Humbert, M.; Guignabert, C. Chronic inflammation within the vascular wall in pulmonary arterial hypertension: More than a spectator. Cardiovasc. Res. 2020, 116, 885–893. [Google Scholar] [CrossRef] [Scilit]
  7. Coons, J.C.; Pogue, K.; Kolodziej, A.R.; Hirsch, G.A.; George, M.P. Pulmonary Arterial Hypertension: A Pharmacotherapeutic Update. Curr. Cardiol. Rep. 2019, 22, 141. [Google Scholar] [CrossRef] [Scilit]
  8. Mayeux, J.D.; Pan, I.Z.; Dechand, J.; Jacobs, J.A.; Jones, T.L.; McKellar, S.H.; Beck, E.; Hatton, N.D.; Ryan, J.J. Management of Pulmonary Arterial Hypertension. Curr. Cardiovasc. Risk Rep. 2021, 15, 2. [Google Scholar] [CrossRef] [Scilit]
  9. Kozłowska, H.; Baranowska, M.; Schlicker, E.; Kozłowski, M.; Laudański, J.; Malinowska, B. Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J. Hypertens. 2007, 25, 2240–2248. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Hornig, B. Endothelial vasodilatory cannabinoid receptor in the human pulmonary artery: A future option in the therapy of pulmonary hypertension? J. Hypertens. 2007, 25, 2202–2203. [Google Scholar] [CrossRef] [Scilit]
  11. ElSohly, M.A.; Radwan, M.M.; Gul, W.; Chandra, S.; Galal, A. Phytochemistry of Cannabis sativa L. Prog. Chem. Org. Nat. Prod. 2017, 103, 1–36. [Google Scholar] [CrossRef] [Scilit]
  12. Malinowska, B.; Toczek, M.; Pędzińska-Betiuk, A.; Schlicker, E. Cannabinoids in arterial, pulmonary and portal hypertension-mechanisms of action and potential therapeutic significance. Br. J. Pharmacol. 2019, 176, 1395–1411. [Google Scholar] [CrossRef] [Scilit]
  13. Laezza, C.; Pagano, C.; Navarra, G.; Pastorino, O.; Proto, M.C.; Fiore, D.; Piscopo, C.; Gazzerro, P.; Bifulco, M. The Endocannabinoid System: A Target for Cancer Treatment. Int. J. Mol. Sci. 2020, 21, 747. [Google Scholar] [CrossRef] [Scilit]
  14. Stanley, C.P.; O’Sullivan, S.E. Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. Pharmacol. Res. 2014, 81, 74–82. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Bondarenko, A.I. Endothelial atypical cannabinoid receptor: Do we have enough evidence? Br. J. Pharmacol. 2014, 171, 5573–5588. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Pacher, P.; Kogan, N.M.; Mechoulam, R. Beyond THC and Endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 2020, 60, 637–659. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Alexander, S.P.H.; Christopoulos, A.; Davenport, A.P.; Kelly, E.; Mathie, A.; Peters, J.A.; Veale, E.L.; Armstrong, J.F.; Faccenda, E.; Harding, S.D.; et al. The Concise Guide to Pharmacology 2019/20: G protein-coupled receptors. Br. J. Pharmacol. 2019, 176, S21–S141. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Wahn, H.; Wolf, J.; Kram, F.; Frantz, S.; Wagner, J.A. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H2491–H2496. [Google Scholar] [CrossRef] [Scilit]
  19. Sadowska, O.; Baranowska-Kuczko, M.; Gromotowicz-Popławska, A.; Biernacki, M.; Kicman, A.; Malinowska, B.; Kasacka, I.; Krzyżewska, A.; Kozłowska, H. Cannabidiol Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats. Int. J. Mol. Sci. 2020, 21, 7077. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Wenzel, D.; Matthey, M.; Bindila, L.; Lerner, R.; Lutz, B.; Zimmer, A.; Fleischmann, B.K. Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction. Proc. Natl. Acad. Sci. USA 2013, 110, 18710–18715. [Google Scholar] [CrossRef] [Scilit]
  21. Karpińska, O.; Baranowska-Kuczko, M.; Kloza, M.; Ambrożewicz, E.; Kozłowski, T.; Kasacka, I.; Malinowska, B.; Kozłowska, H. Activation of CB1 receptors by 2-arachidonoylglycerol attenuates vasoconstriction induced by U46619 and angiotensin II in human and rat pulmonary arteries. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2017, 312, R883–R893. [Google Scholar] [CrossRef] [Scilit]
  22. Baranowska-Kuczko, M.; Kozłowska, H.; Kloza, M.; Sadowska, O.; Kozłowski, M.; Kusaczuk, M.; Kasacka, I.; Malinowska, B. Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: Modification by hypertension and the potential pharmacological opportunities. J. Hypertens. 2020, 38, 896–911. [Google Scholar] [CrossRef] [Scilit]
  23. Karpińska, O.; Baranowska-Kuczko, M.; Malinowska, B.; Kloza, M.; Kusaczuk, M.; Gęgotek, A.; Golec, P.; Kasacka, I.; Kozłowska, H. Mechanisms of l-alpha-lysophosphatidylinositol-induced relaxation in human pulmonary arteries. Life Sci. 2018, 192, 38–45. [Google Scholar] [CrossRef] [Scilit]
  24. Baranowska-Kuczko, M.; Kozłowska, H.; Kozłowski, M.; Schlicker, E.; Kloza, M.; Surażyński, A.; Grzęda, E.; Malinowska, B. Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries. Naunyn Schmiedebergs Arch. Pharmacol. 2014, 387, 477–486. [Google Scholar] [CrossRef] [Scilit]
  25. Zou, S.; Kumar, U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int. J. Mol. Sci. 2018, 19, 833. [Google Scholar] [CrossRef] [Scilit]
  26. Irrera, N.; D’Ascola, A.; Pallio, G.; Bitto, A.; Mannino, F.; Arcoraci, V.; Rottura, M.; Ieni, A.; Minutoli, L.; Metro, D.; et al. β-Caryophyllene Inhibits Cell Proliferation through a Direct Modulation of CB2 Receptors in Glioblastoma Cells. Cancers 2020, 12, 1038. [Google Scholar] [CrossRef] [Scilit]
  27. Picciolo, G.; Pallio, G.; Altavilla, D.; Vaccaro, M.; Oteri, G.; Irrera, N.; Squadrito, F. β-Caryophyllene Reduces the Inflammatory Phenotype of Periodontal Cells by Targeting CB2 Receptors. Biomedicines 2020, 8, 164. [Google Scholar] [CrossRef] [Scilit]
  28. Irrera, N.; D’Ascola, A.; Pallio, G.; Bitto, A.; Mazzon, E.; Mannino, F.; Squadrito, V.; Arcoraci, V.; Minutoli, L.; Campo, G.M.; et al. β-Caryophyllene Mitigates Collagen Antibody Induced Arthritis (CAIA) in Mice Through a Cross-Talk between CB2 and PPAR-γ Receptors. Biomolecules 2019, 9, 326. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Kicman, A.; Toczek, M. The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease. Int. J. Mol. Sci. 2020, 21, 6740. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Toczek, M.; Malinowska, B. Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci. 2018, 204, 20–45. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Di Marzo, V.; Ligresti, A.; Cristino, L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int. J. Obes. 2009, 2, S18–S24. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Meccariello, R.; Santoro, A.; D’Angelo, S.; Morrone, R.; Fasano, S.; Viggiano, A.; Pierantoni, R. The Epigenetics of the Endocannabinoid System. Int. J. Mol. Sci. 2020, 21, 1113. [Google Scholar] [CrossRef] [Scilit]
  33. Calder, P.C. Eicosanoids. Essays Biochem. 2020, 64, 423–441. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Malinowska, B.; Baranowska-Kuczko, M.; Schlicker, E. Triphasic blood pressure responses to cannabinoids: Do we understand the mechanism? Br. J. Pharmacol. 2012, 165, 2073–2088. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Su, E.N.; Kelly, M.E.; Cringle, S.J.; Yu, D.Y. Role of Endothelium in Abnormal Cannabidiol-Induced Vasoactivity in Retinal Arterioles. Investig. Ophthalmol. Vis. Sci. 2015, 56, 4029–4037. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Ho, W.S.; Zheng, X.; Zhang, D.X. Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol. Br. J. Pharmacol. 2015, 172, 5251–5264. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Stanley, C.P.; Hind, W.H.; Tufarelli, C.; O’Sullivan, S.E. Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc. Res. 2015, 107, 568–578. [Google Scholar] [CrossRef] [Scilit]
  38. Stanley, C.P.; Hind, W.H.; Tufarelli, C.; O’Sullivan, S.E. The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries. Pharmacol. Res. 2016, 113, 356–363. [Google Scholar] [CrossRef] [Scilit]
  39. Suleimani, Y.M.; Al Mahruqi, A.S. The endogenous lipid N-arachidonoyl glycine is hypotensive and nitric oxide-cGMP-dependent vasorelaxant. Eur. J. Pharmacol. 2017, 794, 209–215. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Zong, Y.; Zhou, X.; Cheng, J.; Yu, J.; Wu, J.; Jiang, C. Cannabinoids Regulate the Diameter of Pericyte-Containing Retinal Capillaries in Rats. Cell. Physiol. Biochem. 2017, 43, 2088–2101. [Google Scholar] [CrossRef] [Scilit]
  41. López-Dyck, E.; Andrade-Urzúa, F.; Elizalde, A.; Ferrer-Villada, T.; Dagnino-Acosta, A.; Huerta, M.; Osuna-Calleros, Z.; Rangel-Sandoval, C.; Sánchez-Pastor, E. ACPA and JWH-133 modulate the vascular tone of superior mesenteric arteries through cannabinoid receptors, BKCa channels, and nitric oxide dependent mechanisms. Pharmacol. Rep. 2017, 69, 1131–1139. [Google Scholar] [CrossRef] [Scilit]
  42. Baranowska-Kuczko, M.; Kozłowska, H.; Kloza, M.; Harasim-Symbor, E.; Biernacki, M.; Kasacka, I.; Malinowska, B. Beneficial Changes in Rat Vascular Endocannabinoid System in Primary Hypertension and under Treatment with Chronic Inhibition of Fatty Acid Amide Hydrolase by URB597. Int. J. Mol. Sci. 2021, 22, 4833. [Google Scholar] [CrossRef] [Scilit]
  43. Sánchez-Pastor, E.; Andrade, F.; Sánchez-Pastor, J.M.; Elizalde, A.; Huerta, M.; Virgen-Ortiz, A.; Trujillo, X.; Rodríguez-Hernández, A. Cannabinoid receptor type 1 activation by arachidonylcyclopropylamide in rat aortic rings causes vasorelaxation involving calcium-activated potassium channel subunit alpha-1 and calcium channel, voltage-dependent, L type, alpha 1C subunit. Eur. J. Pharmacol. 2014, 729, 100–106. [Google Scholar] [CrossRef] [Scilit]
  44. MacIntyre, J.; Dong, A.; Straiker, A.; Zhu, J.; Howlett, S.E.; Bagher, A.; Denovan-Wright, E.; Yu, D.Y.; Kelly, M.E. Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. Eur. J. Pharmacol. 2014, 735, 105–114. [Google Scholar] [CrossRef] [Scilit]
  45. Wheal, A.J.; Cipriano, M.; Fowler, C.J.; Randall, M.D.; O’Sullivan, S.E. Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation. J. Pharmacol. Exp. Ther. 2014, 351, 457–466. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Wheal, A.J.; Jadoon, K.; Randall, M.D.; O’Sullivan, S.E. In Vivo Cannabidiol Treatment Improves Endothelium-Dependent Vasorelaxation in Mesenteric Arteries of Zucker Diabetic Fatty Rats. Front. Pharmacol. 2017, 8, 248. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Baranowska-Kuczko, M.; Kozłowska, H.; Kloza, M.; Karpińska, O.; Toczek, M.; Harasim, E.; Kasacka, I.; Malinowska, B. Protective role of cannabinoid CB1 receptors and vascular effects of chronic administration of FAAH inhibitor URB597 in DOCA-salt hypertensive rats. Life Sci. 2016, 151, 288–299. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Karpińska, O.; Baranowska-Kuczko, M.; Kloza, M.; Kozłowska, H. Endocannabinoids modulate Gq/11 protein-coupled receptor agonist-induced vasoconstriction via a negative feedback mechanism. J. Pharm. Pharmacol. 2018, 70, 214–222. [Google Scholar] [CrossRef] [Scilit]
  49. Clark, A.; Tawhai, M. Pulmonary Vascular Dynamics. Compr. Physiol. 2019, 9, 1081–1100. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  50. Mark Evans, A.; Ward, J.P. Hypoxic pulmonary vasoconstriction—Invited article. Adv. Exp. Med. Biol. 2009, 648, 351–360. [Google Scholar] [CrossRef] [Scilit]
  51. Suresh, K.; Shimoda, L.A. Lung Circulation. Compr. Physiol. 2016, 6, 897–943. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Su, J.Y.; Vo, A.C. 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur. J. Pharmacol. 2007, 559, 189–195. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Kozłowska, H.; Baranowska, M.; Schlicker, E.; Kozłowski, M.; Laudański, J.; Malinowska, B. Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br. J. Pharmacol. 2008, 155, 1034–1042. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Baranowska-Kuczko, M.; MacLean, M.R.; Kozłowska, H.; Malinowska, B. Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. Pharmacol. Res. 2012, 66, 251–259. [Google Scholar] [CrossRef] [Scilit]
  55. Hopps, J.J.; Dunn, W.R.; Randall, M.D. Enhanced vasorelaxant effects of the endocannabinoid-like mediator, oleamide, in hypertension. Eur. J. Pharmacol. 2012, 684, 102–107. [Google Scholar] [CrossRef] [Scilit]
  56. Milman, G.; Maor, Y.; Abu-Lafi, S.; Horowitz, M.; Gallily, R.; Batkai, S.; Mo, F.M.; Offertaler, L.; Pacher, P.; Kunos, G. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc. Natl. Acad. Sci. USA 2006, 103, 2428–2433. [Google Scholar] [CrossRef] [Scilit]
  57. Ren, S.Y.; Wang, Z.Z.; Zhang, Y.; Chen, N.H. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. Acta Pharmacol. Sin. 2020, 41, 1263–1271. [Google Scholar] [CrossRef] [Scilit]
  58. Kozak, K.R.; Marnett, L.J. Oxidative metabolism of endocannabinoids. Prostagland. Leukot. Essent. Fat. Acids 2002, 66, 211–220. [Google Scholar] [CrossRef] [Scilit]
  59. Herradón, E.; Martín, M.I.; López-Miranda, V. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br. J. Pharmacol. 2007, 152, 699–708. [Google Scholar] [CrossRef] [Scilit]
  60. Vachiery, J.L.; Huez, S.; Gillies, H.; Layton, G.; Hayashi, N.; Gao, X.; Naeije, R. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br. J. Pharmacol. 2011, 71, 289–292. [Google Scholar] [CrossRef] [Scilit]
  61. Merkus, D.; de Beer, V.J.; Houweling, B.; Duncker, D.J. Control of pulmonary vascular tone during exercise in health and pulmonary hypertension. Pharmacol. Ther. 2008, 119, 242–263. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  62. Kloza, M.; Baranowska-Kuczko, M.; Toczek, M.; Kusaczuk, M.; Sadowska, O.; Kasacka, I.; Kozłowska, H. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of KCa2.x and KCa3.1 Channels. Int. J. Mol. Sci. 2019, 20, 4118. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Murtaza, G.; Mermer, P.; Goldenberg, A.; Pfeil, U.; Paddenberg, R.; Weissmann, N.; Lochnit, G.; Kummer, W. TASK-1 potassium channel is not critically involved in mediating hypoxic pulmonary vasoconstriction of murine intra-pulmonary arteries. PLoS ONE 2017, 12, e0174071. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Hwang, M.H.; Lim, J.H.; Yun, H.I.; Rhee, M.H.; Cho, J.Y.; Hsu, W.H.; Park, S.C. Surfactin C inhibits the lipopolysaccharide-induced transcription of interleukin-1beta and inducible nitric oxide synthase and nitric oxide production in murine RAW 264.7 cells. Biotechnol. Lett. 2005, 27, 1605–1608. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Zoratti, C.; Kipmen-Korgun, D.; Osibow, K.; Malli, R.; Graier, W.F. Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br. J. Pharmacol. 2003, 140, 1351–1362. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Bondarenko, A.I. Cannabinoids and Cardiovascular System. Adv. Exp. Med. Biol. 2019, 1162, 63–87. [Google Scholar] [CrossRef] [Scilit]
  67. Parmar, N.; Ho, W.S. N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br. J. Pharmacol. 2010, 160, 594–603. [Google Scholar] [CrossRef] [Scilit]
  68. Bondarenko, A.I.; Drachuk, K.; Panasiuk, O.; Sagach, V.; Deak, A.T.; Malli, R. N-arachidonoyl glycine suppresses Na+/Ca2+ exchanger-mediated Ca2+ entry into endothelial cells and activates BK channels independently of G-protein coupled receptors. Br. J. Pharmacol. 2013, 169, 933–948. [Google Scholar] [CrossRef] [Scilit]
  69. Godlewski, G.; Offertáler, L.; Osei-Hyiaman, D.; Mo, F.M.; Harvey-White, J.; Liu, J.; Davis, M.I.; Zhang, L.; Razdan, R.K.; Milman, G.; et al. The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels. J. Pharmacol. Exp. Ther. 2009, 328, 351–361. [Google Scholar] [CrossRef] [Scilit]
  70. McHugh, D.; Page, J.; Dunn, E.; Bradshaw, H.B. Δ(9)-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br. J. Pharmacol. 2012, 165, 2414–2424. [Google Scholar] [CrossRef] [Scilit]
  71. Zhang, X.; Ye, L.; Huang, Y.; Ding, X.; Wang, L. The potential role of TRPV1 in pulmonary hypertension: Angel or demon? Channels 2019, 13, 235–246. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  72. Xu, Y.; Gu, Q.; Qu, C. Capsaicin pretreatment reversed pulmonary arterial hypertension by alleviating inflammation via p38MAPK pathway. Exp. Lung Res. 2017, 43, 8–18. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Addison, M.P.; Singh, T.U.; Parida, S.; Choudhury, S.; Kasa, J.K.; Sukumaran, S.V.; Darzi, S.A.; Kandasamy, K.; Singh, V.; Kumar, D.; et al. NO synthase inhibition attenuates EDHF-mediated relaxation induced by TRPV4 channel agonist GSK1016790A in the rat pulmonary artery: Role of TxA2. Pharmacol. Rep. 2016, 68, 620–626. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  74. Dryn, D.; Melnyk, M.; Kizub, I.; Hu, H.; Soloviev, A.; Zholos, A. The Role of TRPV4 Cation Channels in the Regulation of Phenylephrine-Induced Contraction of Rat Pulmonary Arter. Fiziol. Zh. 2016, 62, 79–86. [Google Scholar] [CrossRef] [Scilit]
  75. Randhawa, P.K.; Jaggi, A.S. TRPV4 channels: Physiological and pathological role in cardiovascular system. Basic Res. Cardiol. 2015, 110, 54. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Kozłowska, H.; Baranowska-Kuczko, M.; Schlicker, E.; Kozłowski, M.; Kloza, M.; Malinowska, B. Relaxation of human pulmonary arteries by PPARγ agonists. Naunyn Schmiedebergs Arch. Pharmacol. 2013, 386, 445–453. [Google Scholar] [CrossRef] [Scilit]
  77. Hansmann, G.; Wagner, R.A.; Schellong, S.; Perez, V.A.; Urashima, T.; Wang, L.; Sheikh, A.Y.; Suen, R.S.; Stewart, D.J.; Rabinovitch, M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007, 115, 1275–1284. [Google Scholar] [CrossRef] [Scilit]
  78. Guignabert, C.; Alvira, C.M.; Alastalo, T.P.; Sawada, H.; Hansmann, G.; Zhao, M.; Wang, L.; El-Bizri, N.; Rabinovitch, M. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297, L1082–L1090. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  79. Rabinovitch, M. PPARgamma and the pathobiology of pulmonary arterial hypertension. Adv. Exp. Med. Biol. 2010, 661, 447–458. [Google Scholar] [CrossRef] [Scilit]
  80. Ameshima, S.; Golpon, H.; Cool, C.D.; Chan, D.; Vandivier, R.W.; Gardai, S.J.; Wick, M.; Nemenoff, R.A.; Geraci, M.W.; Voelkel, N.F. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res. 2003, 92, 1162–1169. [Google Scholar] [CrossRef] [Scilit]
  81. Lu, X.; Murphy, T.C.; Nanes, M.S.; Hart, C.M. PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299, L559–L566. [Google Scholar] [CrossRef] [Scilit]
  82. Nisbet, R.E.; Bland, J.M.; Kleinhenz, D.J.; Mitchell, P.O.; Walp, E.R.; Sutliff, R.L.; Hart, C.M. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am. J. Respir. Cell Mol. Biol. 2010, 42, 482–490. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  83. O’Sullivan, S.E.; Sun, Y.; Bennett, A.J.; Randall, M.D.; Kendall, D.A. Time-dependent vascular actions of cannabidiol in the rat aorta. Eur. J. Pharmacol. 2009, 612, 61–68. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  84. Chang, C.Y.; Shih, H.J.; Huang, I.T.; Tsai, P.S.; Chen, K.J.; Huang, H.J. Magnesium sulfate mitigates the progression of monocrotaline pulmonary hypertension in rats. Int. J. Mol. Sci. 2019, 20, 4622. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  85. Hill, N.S.; Gillespie, M.N.; McMurtry, I.F. Fifty years of monocrotaline-induced pulmonary hypertension: What has it meant to the field? Chest 2017, 152, 1106–1108. [Google Scholar] [CrossRef] [Scilit]
  86. Remiszewski, P.; Jarocka-Karpowicz, I.; Biernacki, M.; Jastrząb, A.; Schlicker, E.; Toczek, M.; Harasim-Symbor, E.; Pędzińska-Betiuk, A.; Malinowska, B. Chronic cannabidiol administration fails to diminish blood pressure in rats with primary and secondary hypertension despite its effects on cardiac and plasma endocannabinoid system, oxidative stress and lipid metabolism. Int. J. Mol. Sci. 2020, 21, 1295. [Google Scholar] [CrossRef] [Scilit]
  87. Lu, X.; Zhang, J.; Liu, H.; Ma, W.; Yu, L.; Tan, X.; Wang, S.; Ren, F.; Li, X.; Li, X. Cannabidiol attenuates pulmonary arterial hypertension by improving vascular smooth muscle cells mitochondrial function. Theranostics 2021, 11, 5267–5278. [Google Scholar] [CrossRef] [Scilit]
  88. Duerr, G.D.; Feißt, A.; Halbach, K.; Verfuerth, L.; Gestrich, C.; Wenzel, D.; Zimmer, A.; Breuer, J.; Dewald, O. CB2-deficiency is associated with a stronger hypertrophy and remodeling of the right ventricle in a murine model of left pulmonary artery occlusion. Life Sci. 2018, 215, 96–105. [Google Scholar] [CrossRef] [Scilit]
Ijms 22 10048 g001
Figure 1. Concentration–response curves of endocannabinoid anandamide (AEA) and endocannabinoid-like molecules: N-arachidonoyl-L-serine (ARA-S), oleamide; cis-9-octadecenoamide (ODA), noladin ether; 2-arachidonyl-glycerol ether (2-AGE) or vehicles for their vasorelaxant effects on endothelium-intact rings of isolated human pulmonary artery. Results are expressed as percentage relaxation of the isometric contraction induced by serotonin (5-HT, 1 µM). Mean ± SEM of 5 tissues is shown for each curve. In few cases, SEM is smaller than or equal to the size of symbols.
Figure 1. Concentration–response curves of endocannabinoid anandamide (AEA) and endocannabinoid-like molecules: N-arachidonoyl-L-serine (ARA-S), oleamide; cis-9-octadecenoamide (ODA), noladin ether; 2-arachidonyl-glycerol ether (2-AGE) or vehicles for their vasorelaxant effects on endothelium-intact rings of isolated human pulmonary artery. Results are expressed as percentage relaxation of the isometric contraction induced by serotonin (5-HT, 1 µM). Mean ± SEM of 5 tissues is shown for each curve. In few cases, SEM is smaller than or equal to the size of symbols.
Ijms 22 10048 g001
Ijms 22 10048 g002
Figure 2. The location of the endocannabinoid system components and potential mechanisms involved in the cannabinoid-induced vasorelaxation in pulmonary arteries. Abbreviations: 2-AG, 2-arachidonoylglycerol; 2-AGE, noladin ether; AA, arachidonic acid; AEA, anandamide; Abn-CBD, abnormal cannabidiol; APA, apamin, KCa2.3 inhibitor; AM251, CB1-R antagonist; AM630, CB2-R antagonist; CB1-R, cannabinoid receptor type 1; CB2-R, cannabinoid receptor type 2; CBD, cannabidiol; CHTX, charybdotoxin, KCa1.1 and KCa3.1 inhibitor; CID16020046, GPR55 receptor antagonist; COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; EA, ethanolamine; eCB, historically called endothelial cannabinoid receptor; eNOS, endothelial nitric oxide synthase; EP4, prostanoid EP4 receptor; FAAH, fatty acid amide hydrolase; GPR18, G protein-coupled receptor 18; GPR55, G-protein-coupled receptor 55; GW9662, PPAR-γ receptor antagonist; IBX, iberiotoxin, KCa1.1 inhibitor; IP, prostacyclin receptor; INDO, indometacin, COX-1/COX-2 inhibitor; JZL184, monoacylglycerol lipase inhibitor; KCa2.3, KCa3.1, and KCa1.1, calcium-activated potassium channels with small, intermediate, and large conductivity for K+, respectively; LPI, l-alpha-lysophosphatidylinositol; L-NAME, N G-nitro-l-arginine methyl ester, eNOS inhibitor; L161982, EP4 receptor antagonist; Kca, calcium-activated potassium channels; MAGL, monoacylglycerol lipase; nimesulid, COX-2 inhibitor; O-1918, eCB receptor antagonist; pEC50, the negative logarithm of the concentration causing a half-maximum effect; PGE2, prostaglandin E2; PGI2, prostacyclin; PPAR-γ, peroxisome proliferator-activated receptor-gamma; RO1138452, IP receptor antagonist; SR141716, rimonabant, CB1-R antagonist; SR144528, CB2-R antagonist; TEA, tetraethylammonium, KCa2.3 and KCa3.1 inhibitor; TRAM-34, triarylmethane-34, KCa2.3 inhibitor; TRPV1, transient receptor potential vanilloid 1; TXA2, thromboxane A2; UCL1684, 6,10-diaza-3(1,3)8,(1,4)-dibenzena-1,5(1,4)-diquinolinacy clodecaphane, KCa2.3 inhibitor; URB597, FAAH inhibitor; VIR, virodhamine. This figure was prepared using a template on the Servier Medical Art website.
Figure 2. The location of the endocannabinoid system components and potential mechanisms involved in the cannabinoid-induced vasorelaxation in pulmonary arteries. Abbreviations: 2-AG, 2-arachidonoylglycerol; 2-AGE, noladin ether; AA, arachidonic acid; AEA, anandamide; Abn-CBD, abnormal cannabidiol; APA, apamin, KCa2.3 inhibitor; AM251, CB1-R antagonist; AM630, CB2-R antagonist; CB1-R, cannabinoid receptor type 1; CB2-R, cannabinoid receptor type 2; CBD, cannabidiol; CHTX, charybdotoxin, KCa1.1 and KCa3.1 inhibitor; CID16020046, GPR55 receptor antagonist; COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; EA, ethanolamine; eCB, historically called endothelial cannabinoid receptor; eNOS, endothelial nitric oxide synthase; EP4, prostanoid EP4 receptor; FAAH, fatty acid amide hydrolase; GPR18, G protein-coupled receptor 18; GPR55, G-protein-coupled receptor 55; GW9662, PPAR-γ receptor antagonist; IBX, iberiotoxin, KCa1.1 inhibitor; IP, prostacyclin receptor; INDO, indometacin, COX-1/COX-2 inhibitor; JZL184, monoacylglycerol lipase inhibitor; KCa2.3, KCa3.1, and KCa1.1, calcium-activated potassium channels with small, intermediate, and large conductivity for K+, respectively; LPI, l-alpha-lysophosphatidylinositol; L-NAME, N G-nitro-l-arginine methyl ester, eNOS inhibitor; L161982, EP4 receptor antagonist; Kca, calcium-activated potassium channels; MAGL, monoacylglycerol lipase; nimesulid, COX-2 inhibitor; O-1918, eCB receptor antagonist; pEC50, the negative logarithm of the concentration causing a half-maximum effect; PGE2, prostaglandin E2; PGI2, prostacyclin; PPAR-γ, peroxisome proliferator-activated receptor-gamma; RO1138452, IP receptor antagonist; SR141716, rimonabant, CB1-R antagonist; SR144528, CB2-R antagonist; TEA, tetraethylammonium, KCa2.3 and KCa3.1 inhibitor; TRAM-34, triarylmethane-34, KCa2.3 inhibitor; TRPV1, transient receptor potential vanilloid 1; TXA2, thromboxane A2; UCL1684, 6,10-diaza-3(1,3)8,(1,4)-dibenzena-1,5(1,4)-diquinolinacy clodecaphane, KCa2.3 inhibitor; URB597, FAAH inhibitor; VIR, virodhamine. This figure was prepared using a template on the Servier Medical Art website.
Ijms 22 10048 g002
Table 1. Expression of the selected components of the endocannabinoid system in pulmonary circulation/lung tissue.
Table 1. Expression of the selected components of the endocannabinoid system in pulmonary circulation/lung tissue.
Endocannabinoid System ComponentsMaterialSpeciesMethodsExpressionReferences
EndotheliumWhole Vascular WallWhole Lung
ligands2-AGlung cellular extractsrabbitLC/MS +[18]
lungrat +[19]
AEAlung cellular extractsrabbitLC/MS +[18]
lungratLC/MS +[19]
mouseLC/MRM +[20]
receptorsCB1-Rpulmonary arteriesratIHC + [21]
WB +
humanWB +
IHC +
+ [22]
CB2-Rpulmonary arterieshumanIHC + [22]
WB + [21]
rat +
TRPV1pulmonary arterieshumanIHC + [22]
GPR18pulmonary arterieshumanIHC + [22]
GPR55pulmonary arterieshumanWB + [23]
IHC+
enzymesFAAHpulmonary arterieshumanWB + [24]
lunghumanWB +
mouse +[20]
rabbitRT-PCR +[18]
+ expression detected. Abbreviations: 2-AG, 2-arachidonoylglycerol; AEA, anandamide; CB1-R, cannabinoid receptor type 1; CB2-R, cannabinoid receptor type 2; FAAH, fatty acid amide hydrolase; GPR18, G-protein-coupled receptor 18; GPR55, G-protein-coupled receptor 55; IHC, immunohistochemistry; LC/MS, liquid chromatography-mass spectrometry; LC/MRM, liquid chromatography-multiple reaction monitoring; RT-PCR, real-time polymerase chain reaction; TRPV1, transient receptor potential vanilloid 1; WB, western blot.
Table 2. The relaxing effects of cannabinoids on systemic vessels (published after 2014).
Table 2. The relaxing effects of cannabinoids on systemic vessels (published after 2014).
LigandBlood VesselpEC50MechanismsReferences
EndoeNOSCOXKCaCB1-RCB2-ReCBOther
AEAhMA5.7↓↓No-↓No↓ [38]
rRet5.2------- [40]
2-AGrRet5.0------- [40]
rMA5.9 *↓-No↓NoNo-TRPV4[36]
2-AGErMA5.6 *No------ [36]
NAGLyrMA-↓↓NoNoNoNo↓ [39]
CBDhMA5.1↓↓No↓↓NoNoTRPV1[37]
rFA 1-No↓↓-No↓NoSOD, EP4[45]
rFA, rA 1--↓↓---- [46]
rMA 1--NoNo---- [46]
rMA 26.0No---NoNo- [22]
rMA 35.5No---NoNo- [22]
rMA 45.9↓---↓↓- [22]
rMA 55.6No---↓No- [22]
Abn-CBDrRet4.5↓No-↓NoNo- [44]
pRet-↓---↓-↓ [35]
WIN 55,212-2rRet5.0↓↓No-↓NoNo [40]
JHW-133rMA--↓---↓- [41]
MethAEArA 66.1------- [47]
rMA 64.9----No--TRPV1[47]
rMA 45.6----↓--TRPV1[47]
rMA 55.6----↓-- [42]
rMA 26.1----No--
ACPArA4.3No--↓No--Cav 1.2[43]
rMA-↓↓-↓↓-- [41]
1 Zucker diabetic fatty rats; 2 WKY, Wistar-Kyoto rats; 3 SHAM, control sham-operated rats; 4 rats with secondary hypertension induced by Deoxycorticosterone acetate-salt (DOCA salt); 5 SHR, spontaneously hypertensive rats; 6 UNX, uninephrectomized normotensive rats; * pEC40; ↓, weakening effect; No, no effect; -, not determined. Abbreviations: 2-AG, 2-arachidonoylglycerol; Abn-CBD, abnormal cannabidiol; ACPA, arachidonylcyclopropylamide; AEA, anandamide; ARA-S, N-arachidonoyl L-serine; Cav 1.2, voltage-dependent L-type calcium channel subunit alpha-1C; CB1-R, cannabinoid receptor type 1; CB2-R, cannabinoid receptor type 2; CBD, cannabidiol; COX, cyclooxygenase; eCB, historically called endothelial cannabinoid receptor; endo, endothelium; eNOS, endothelial nitric oxide synthase; EP4, prostanoid EP4 receptor; FAAH, fatty acid amide hydrolase; hMA, human mesenteric artery; JHW-133, 3-(1,1-dimethylbutyl)-6aR,7,10,10aR-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran, synthetic cannabinoid; KCa, calcium-activated potassium channels; MethAEA, methanandamide; NAGLy, N-Arachidonylglycine; pEC50, the negative logarithm of the concentration causing a half-maximum effect; pRet, pig retinal arterioles, PTX: pertussis toxin; rA, rat aorta; rCA, rat coronary artery; rFA, rat femoral artery; rMA, rat mesenteric artery; rRet, rat retinal capillaries; SOD, superoxide dismutase; TRPV1, transient receptor potential vanilloid 1; TRPV4, transient receptor potential vanilloid 4; WIN 55,212-2, [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate, synthetic cannabinoid; VIR, virodhamine.
Table 3. The vasorelaxant effects of cannabinoids on the pulmonary vessels.
Table 3. The vasorelaxant effects of cannabinoids on the pulmonary vessels.
SpeciesLigandsVasoconstrictorpEC50Concentration [μmol/L]EndotheliumInhibitorsKCa InhibitorsAntagonists
eNOSFAAHCOX-1
COX-2		COX-2MAGLKCl [60/120 mM]KCa1.1
KCa3.1		KCa1.1KCa2.3KCa3.1CB1-RCB2-ReCBIPEP4TRPV1PPAR-γReferences
L-NAMEURB597INDONIMESJZL184CHTXIBTXUCL164/
APA *		TRAM-34AM251/
SR141716 *		AM630/
SR144528 *		O-1918RO1138452L161982CAPSGW9662
humanAEA 15-HT5.20.1–100------------------[9]
AEAU466195.00.1–100↓↓↓↓↓-↓-↓--NoNo *↓↓-No-[24]
VIR5-HT5.10.1–100↓↓3↓↓--↓↓-↓ *-NoNo *↓
6.3 2		--No-[53]
2-AGU466195.40.01–30↓-No--↑-----↓
6.9 2		------[21]
LPIPhe6.40.01–3↓↓-No- ↓-↓↓↓No-↓
5.8 2		---↓[23]
CBDU466195.00.1–30↓No-↓↓-↓-↓↓↓NoNoNo↓
5.8 2		↓
6.6 2		↓↓[22]
Abn-CBD5-HT4.80.1–100↓No-No--↓↓-↓ *---↓
5.1 2		----[9]
rabbit2-AGEpCa 6.3-0.1–3↓----------↓/
↓ *		-↓----[52]
Abn-CBDpCa 6.3-0.01–0.3↓----------↓/
↓ *		-↓----[52]
ratAEAU466195.00.1–100↓↓↓↓--↓↓-↓ *-NoNo↓
6.0 2		↓
6.2 2		-No-[54]
Abn-CBDU466194.60.1–100↓-----↓----NoNo↓
5.4 2		--No-[54]
1 in the presence of AM251; 2 antagonistic potency (pA2); 3 statistically significant influence was noticed for virodhamine (30 μm) only; *, used antagonists; ↑, enhancing effect; ↓, weakening effect; No, no effect; -, not determined. Abbreviations: 2-AG, 2-arachidonoylglycerol; 2-AGE, noladin ether; 5-HT, serotonin; AEA, anandamide; Abn-CBD, abnormal cannabidiol; APA, apamin, blocker of KCa2.3; AM251, CB1-R antagonist; AM630, CB2-R antagonist; CAPS, capsazepine; CB1-R, cannabinoid receptor type 1; CB2-R, cannabinoid receptor type 2; CBD, cannabidiol; CHTX, charybdotoxin, KCa1.1 and KCa3.1 inhibitor; COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; eCB, historically called endothelial cannabinoid receptor; eNOS, endothelial nitric oxide synthase; EP4, prostanoid EP4 receptor; FAAH, fatty acid amide hydrolase; GW9662, 2-chloro-5-nitrobenzanilide, PPAR-γ receptor antagonist; IBX, iberiotoxin, KCa1.1 inhibitor; IP, prostacyclin receptor; INDO, indometacin, COX-1/COX-2 inhibitor; JZL184, monoacylglycerol lipase inhibitor; KCa, calcium-activated potassium channels; KCa2.3, KCa3.1, KCa1.1, calcium-activated potassium channels with small, intermediate and large conductivity for K+, respectively; L-NAME, N G-nitro-l-arginine methyl ester, eNOS inhibitor; L-161982, EP4 receptor antagonist; LPI, L-alpha-lysophosphatidylinositol; MAGL, monoacylglycerol lipase; nimes: nimesulid, COX-2 inhibitor; O-1918, eCB receptor antagonist; pCa 6.3, buffer, containing free Ca2+ concentrations of 0.316 μM; pEC50, the negative logarithm of the concentration causing a half-maximum effect; Phe, phenylephrine; PPAR-γ, peroxisome proliferator-activated receptor gamma; RO1138452, IP receptor antagonist; SR141716, rimonabant, CB1-R antagonist; SR144528, CB2-R receptor antagonist; TRAM-34, triarylmethane-34, KCa2.3 inhibitor; TRPV1, transient receptor potential vanilloid 1; U46619, prostanoid TP receptor agonist; UCL1684, 6,10-diaza-3(1,3)8,(1,4)-dibenzena-1,5(1,4)-diquinolinacy clodecaphane, KCa2.3 inhibitor; URB597, FAAH inhibitor; VIR, virodhamine.
Table 4. Influence of cannabinoids on pulmonary circulation in in vivo or in vitro studies.
Table 4. Influence of cannabinoids on pulmonary circulation in in vivo or in vitro studies.
SpeciesModelCannabinoidDose/Concentration/Route
of Administration		EffectReferences
rabbitisolated, ventilated, and buffer-perfused lungAEA0.5–5 μM↑ pulmonary arterial pressure[18]
2-AG0.2–0.4 μM
ratMCT-induced PH
(60 mg/kg)		CBD10 mg/kg for 21 days,
preventive model, i.p.		↓ RVSP
↓ pulmonary arterial hypertrophy
No right ventricular hypertrophy
↑ blood oxygen saturation
↑ concentration of endogenous cannabinoids in lung tissue: AEA,
2-LG, LEA, POEA, EPEA and NAGly
↓ the plasma concentrations of PAI-1 and t-PA		[19]
↓ RVSP
↓ pulmonary arterial hypertrophy
↓ right ventricular hypertrophy		[87]
mousesugen-hypoxia-induced PHCBD10 mg/kg for 21 days,
preventive model, i.g.		↓ RVSP
↓ pulmonary arterial hypertrophy
↓ right ventricular hypertrophy
↓ mRNA levels of IL-6 and TNF-α in lung tissue		[87]
10 mg/kg for 14 days
after PH induction,
therapeutic model i.g.		↓ RVSP
↓ pulmonary arterial hypertrophy
↓ right ventricular hypertrophy
PH-PASMC10 μM for 2 h↓ hyperproliferation
↓ mRNA levels of chemokine CCL2 and CXCL10
↓ oxidative stress in mitochondria
humanhypoxia induced HPASMC cell cultureCBD10 μM for 2 h and
12 h		recover the dysfunctional mitochondria in hypoxia condition:
↓ oxidative stress
↓ excessive glycolysis		[87]
↑, increase; ↓, decrease; No, no change. Abbreviations: 2-AG, 2-arachidonoylglycerol; 2-LG, linoleoylglycerol; AEA, anandamide; CBD, cannabidiol; CCL2, monocyte chemoattractant protein-1; CXCL10, chemokine (C-X-C motif) ligand 10; EPEA, eicosapentaenoyl ethanolamide; i.g., intragastric administration; IL-6, interleukin-6; i.p., intraperitoneal injections; LEA, linolenoyl ethanolamide; NAGLy, N-arachidonoyl glycine; PH, pulmonary hypertension; PAI-1, plasminogen activator inhibitor-1; PASMCs, pulmonary artery smooth muscle cells; POEA, palmitoleoyl ethanolamide; RVSP, right ventricular systolic pressure; TNF-α, tumour necrosis factor-alpha; tPA, tissue plasminogen activator.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Krzyżewska, A.; Baranowska-Kuczko, M.; Mińczuk, K.; Kozłowska, H. Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension. Int. J. Mol. Sci. 2021, 22, 10048. https://doi.org/10.3390/ijms221810048

AMA Style

Krzyżewska A, Baranowska-Kuczko M, Mińczuk K, Kozłowska H. Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension. International Journal of Molecular Sciences. 2021; 22(18):10048. https://doi.org/10.3390/ijms221810048

Chicago/Turabian Style

Krzyżewska, Anna, Marta Baranowska-Kuczko, Krzysztof Mińczuk, and Hanna Kozłowska. 2021. "Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension" International Journal of Molecular Sciences 22, no. 18: 10048. https://doi.org/10.3390/ijms221810048

APA Style

Krzyżewska, A., Baranowska-Kuczko, M., Mińczuk, K., & Kozłowska, H. (2021). Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension. International Journal of Molecular Sciences, 22(18), 10048. https://doi.org/10.3390/ijms221810048

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop